Catalent Acquires Pharmapak, Australia
Catalent Pharma Solutions recently announced it has acquired Pharmapak Technologies Pty Ltd., a leading pharmaceutical packaging business based in New South Wales, Australia. Enhancing Catalent’s ability to offer integrated solutions to customers, this acquisition provides regional packaging capabilities and complements Catalent’s existing facility in Braeside, Victoria from which Catalent produces oral dose products including softgels, Vegicaps capsules, and OptiShell capsules, for supply throughout Asia Pacific. Financial details were not disclosed.
“This acquisition complements our industry-leading oral dosage form development and manufacturing capabilities with a broader range of packaging options, from bulk supply to finished packs,” said Mark Bisset, President of Catalent Asia Pacific. “Catalent has made substantial recent investments in Asia Pacific with a new facility in China, and last year, we celebrated our 40th year in Japan with a new laboratory and the build-out of more manufacturing capacity. This latest investment is in response to strong, local market demand for both pharmaceutical, over-the-counter (OTC) and Complementary Medicine products.”
The company will continue to operate as Pharmapak Technologies Pty Ltd. and retain its approximately 100 employees, including its leadership team at its existing facility in Dee Why, New South Wales. Pharmapak’s capabilities include primary and secondary packaging of oral pharmaceutical dose forms, including blisters, bottles, and a wide range of tertiary packaging services.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable clinical and commercial product supply. For more information, visit www.catalent.com.
Total Page Views: 1288
